Abstract
In addition to the T helper 1 (Th1) and Th2 lymphocyte subsets, two new subpopulations Th17 and regulatory T (Treg) cells have recently been described. Th17 cells, which produce high levels of interleukin (IL)-17, are dependent on the transcription factor orphan nuclear receptor RORC2/RORγt and have been implicated in exacerbating the immune response to infections. Conversely, Treg cells, either thymus-derived or generated upon TCR activation of naïve T cells, express the transcription factor forkhead box P3 (Foxp3) and have regulatory functions mediated through either direct cell-cell contact or immuno-suppressive cytokines, being able to suppress the activation of T, B and NK cells. Based on the current knowledge of Th17 and Treg cell functions, new therapeutic strategies start to emerge, involving anti-cytokine treatments targeting Th17 functions or cell-based treatments in which Treg cells are generated from T cells either through Foxp3 gene transfer onto T cells with known specificities or transferring specific TCR genes onto Treg cells.
Keywords: T lymphocytes, T cells, T cell subsets, helper T cells, Th17, RORC2, RORγt, regulatory T cells, Treg cells, Foxp3
Infectious Disorders - Drug Targets
Title: Th17 and Treg Cells, Two New Lymphocyte Subpopulations with a Key Role in the Immune Response Against Infection
Volume: 8 Issue: 4
Author(s): Rolando Vernal and Jose A. Garcia-Sanz
Affiliation:
Keywords: T lymphocytes, T cells, T cell subsets, helper T cells, Th17, RORC2, RORγt, regulatory T cells, Treg cells, Foxp3
Abstract: In addition to the T helper 1 (Th1) and Th2 lymphocyte subsets, two new subpopulations Th17 and regulatory T (Treg) cells have recently been described. Th17 cells, which produce high levels of interleukin (IL)-17, are dependent on the transcription factor orphan nuclear receptor RORC2/RORγt and have been implicated in exacerbating the immune response to infections. Conversely, Treg cells, either thymus-derived or generated upon TCR activation of naïve T cells, express the transcription factor forkhead box P3 (Foxp3) and have regulatory functions mediated through either direct cell-cell contact or immuno-suppressive cytokines, being able to suppress the activation of T, B and NK cells. Based on the current knowledge of Th17 and Treg cell functions, new therapeutic strategies start to emerge, involving anti-cytokine treatments targeting Th17 functions or cell-based treatments in which Treg cells are generated from T cells either through Foxp3 gene transfer onto T cells with known specificities or transferring specific TCR genes onto Treg cells.
Export Options
About this article
Cite this article as:
Vernal Rolando and Garcia-Sanz A. Jose, Th17 and Treg Cells, Two New Lymphocyte Subpopulations with a Key Role in the Immune Response Against Infection, Infectious Disorders - Drug Targets 2008; 8 (4) . https://dx.doi.org/10.2174/187152608786734197
DOI https://dx.doi.org/10.2174/187152608786734197 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exploring Mechanisms of MicroRNA Downregulation in Cancer
MicroRNA Recent Advances in T Cell Adoptive Immunotherapy of Cancer
Current Cancer Therapy Reviews Zeolitic Imidazolate Frameworks (ZIF-8) for Biomedical Applications: A Review
Current Medicinal Chemistry Peripheral TRPV1 Receptors As Targets for Drug Development: New Molecules and Mechanisms
Current Pharmaceutical Design SCYL1-BP1 Affects Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells via Cyclin F and RRM2
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Approaches to Chronic Spinal Cord Injury
Current Pharmaceutical Design Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Antioxidant, Pro-Oxidant and Other Biological Activities of Sesquiterpenes
Current Topics in Medicinal Chemistry Animal Models Used for the Evaluation of Antiretroviral Therapies
Current HIV Research Targeting AMPK Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
Current Drug Targets Performance of PET/CT for Detecting the Primary Tumors of Cervical Metastases from Unknown Primary Carcinoma: A Systematic Review and Meta-Analysis
Current Medical Imaging Synthesis and Anticancer Activity of 9-O-Pyrazole Alkyl Substituted Berberine Derivatives
Anti-Cancer Agents in Medicinal Chemistry Antiangiogenic Therapy
Current Pharmaceutical Design Advanced Approaches of Bioactive Peptide Molecules and Protein Drug Delivery Systems
Current Pharmaceutical Design Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy
Current Drug Targets Epigenetic Mechanism Involved in the HBV/HCV-Related Hepatocellular Carcinoma Tumorigenesis
Current Pharmaceutical Design Morin Inhibits Ovarian Cancer Growth through the Inhibition of NF-κB Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Photodynamic Effects of Vitamin K3 on Cervical Carcinoma Cells Activating Mitochondrial Apoptosis Pathways
Anti-Cancer Agents in Medicinal Chemistry Cdc20: A Potential Novel Therapeutic Target for Cancer Treatment
Current Pharmaceutical Design An Overview of Targeting Legumain for Inhibiting Cancers
Current Pharmaceutical Design